Exploring the positive and negative consequences of NF-κB inhibition for the treatment of human disease

Cell Cycle

Volumn 5, Issue 11, 2006, Pages 1160-1163

  Fraser, Christopher C ^a  

^a NONE   (United States)

Author keywords

Apoptosis; Cancer; Development; Drug; Homeostasis; Immune; Inflammation; NF B

Indexed keywords

I KAPPA B; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ML 120B; PROTEIN P50; PROTEIN P52; SYNAPTOTAGMIN; TRANSCRIPTION FACTOR RELB; UNCLASSIFIED DRUG;

CANCER; CELL CYCLE; CELL DEATH; CELL FUNCTION; DIABETES MELLITUS; DRUG INHIBITION; GENE MUTATION; GENETIC ANALYSIS; HOMEOSTASIS; IMMUNE RESPONSE; INFLAMMATION; MUSCLE ATROPHY; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; STROKE;

EID: 33744945025     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.5.11.2773     Document Type: Review

References (86)

1. Ghosh S, May MJ, Kopp EB. NF-κB and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-60.
2. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: The control of NF-[kappa]B activity. Annu Rev Immunol 2000; 18:621-63.
3. Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell 2002; 109:S81-S96.
4. Israel A. The IKK complex: An integrator of all signals that activate NF-κB. Trends in Cell Biol 2000; 10:129-33.
5. Hayden MS, Ghosh S. Signaling to NF-κB. Genes and Dev 2004; 18:2195-224.
6. Zhang G, Ghosh S. Toll-like receptor-mediated NF-κB activation: A phylogenetically conserved paradigm in innate immunity. J Clin Invest 2001; 1:13-19.
7. Akira S, Takeda K. Toll-like receptor signaling. Nat Rev 2004; 4:499-511.
8. Ruland J, Mak TW. Transducing signals from antigen receptors to nuclear factor κB. Imm Rev 2003; 193:93-100.
9. Rueda D, Thome M. Phoshorylation of CARMA1: The linker to NF-κB activation. Immunity 2005; 23:551-5.
10. Aggarwal BB. Signalling pathways of the TNF superfamily: A double edged sword. Nat Rev Immunol 2003; 3:745-56.
11. Legembre P, Barnhart BC, Peter ME. The relevance of NF-κB for CD95 signaling in tumor cells. Cell Cycle 2004; 3:87-91.
12. Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 1999; 18:6853-66.
13. Werner SL, Barken D, Hoffman A. Stimulus specificity of gene expression programs determined by temporal control of IKK activity. Science 2005; 309:1857-61.
14. Cory S, Adams JM. The Bcl2 family: Regulators of cellular life-or -death switch. Nat Rev Cancer 2002; 2:647-56.
15. Danial NN, Korsmeyer SJ. Cell death: Critical control points. Cell 2004; 116:205-19.
16. Kumar A, Takada Y, Boriek AM, Aggarwal BB. Nuclear factor-κB: Its role in health and disease. J Mol Med 2004; 82:434-48.
17. Karin M, Yamamoto Y, Wang QM. The IKK NF-κB system: A treasure trove for drug development. Nat Rev Drug Disc 2004; 3:17-26.
18. Pande V, Ramos MJ. NF-κB in human disease: Current inhibitors and prospects for de novo structure based design of inhibitors. Current Med Chem 2005; 12:357-74.
19. Nagashima K, Sasseville VG, Wen D, Bielecki A, Yang H, Simpson C, Grant E, Hepperle M, Harriman G, Jaffee B, Ocain T, Xu Y, Fraser CC. Rapid TNFR1 dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKKβ. Blood 2006; Epub ahead of print.
20. Barnes PJ, Karin, M. Nuclear factor-κB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336:1066-71.
21. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Invest 2001; 107:135-42.
22. Tak PP, Firestein GS. NF-κB: A key role in inflammatory diseases. J Clin Invest 2001; 107:7-11.
23. Jimi E, Ghosh S. Role of nuclear factor-κB in the immune system and bone. Imm Rev 2005; 208:80-7.
24. Ruocco MG, Karin M. IKKbeta as a arget for treatment of inflammation induced bone loss. Ann Rheum Dis 2005; 64(Suppl 4):81-5.
25. Caramori G, Adcock IM, Ito K. Anti-inflammatory inhibitors of IkappaB kinase in asthma and COPD. Curr Opin Invest Drugs 2004; 5:1141-7.
26. Aggarwal BB. Nuclear factor KB: The enemy within. Cancer Cell 2004; 6:203-8.
27. Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2002; 2:301-10.
28. Haefner B. NF-κB: Arresting a major culprit in cancer. Drug Disc Today 2002; 7:653-63.
29. Richmond A. NF-κB, chemokine gene transcription and tumour growth. Nat Rev Immunol 2002; 2:664-74.
30. Clevers H. At the crossroads of inflammation and cancer. Cell 2004; 118:671-4.
31. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7:211-17.
32. Li Q, Withoff S, Verma IM. Inflammation-associated cancer:NF-κB is the lynchpin. Trends Immunol 2005; 26:318-325.
33. Karin M, Greten FR. NF-κB: Linking inflammation and immunity to cancer development and pregression. Nat Rev Immunol 2005; 5:749-59.
34. Luo JL, Kamata H, Karin M. IKK/NF-κB signaling: Balancing life and death-a new approach to cancer therapy. J Clin Invest 2005; 115:2625-32.
35. Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: The dark side of B-cell differentiation. Nat Rev Immunol 2002; 2:920-32.
36. Panwalkar A, Verstovsek S, Giles F. Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies. Cancer 2004; 100:1578-89.
37. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, Zou Y, Bao S, Hanada N, Saso H, Kobayashi R, Hung MC. IκB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 2004; 117:225-37.
38. Wu JT, Kral JG. The NF-kappaB/IkappaB signaling system: A molecular target in breast cancer therapy. J Surg Res 2005; 123:158-69.
39. Nakanishi C, Toi M. Nuclear Factor-κB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5:297-309.
40. Herrmann O, Baumann B, de Lorenzi R, Muhammad S, Zhang W, Kleesiek J, Malfertheiner M, Kohrmann M, Potrovita I, Maegele I, Beyer C, Burke JR, Hasan MT, Bujard H, Wirth T, Pasparakis M, Schwaninger M. IKK mediates ischemia-induced neuronal death. Nat Med 2005; 11:1322-9.
41. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, Wynshaw-Boris A, Poli G, Olefsky J, Karin M. IKK-β links inflammation to obesity-induced insulin resistance. Nat Med 2005; 111:191-8.
42. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat Med 2005; 111:183-90.
43. Cai D, Frantz JD, Tawa NE Jr, Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ, Shoelson SE. IKKβ/NF-κB activation causes severe muscle wasting in mice. Cell 2004; 119:285-98.
44. Siebenlist U, Brown K, Claudio E. Control of lymphocyte development by nuclear factor-κB. Nat Rev Immunol 2005; 5:435-45.
45. Li Q, Van Antwerp D, Mercurio F, Lee KF, Verma IM. Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science 1999; 284:321-325.
46. Li ZW, Chu W, Hu Y, Delhase M, Deerinck T, Ellisman M, Johnson R, Karin M. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med 1999; 189:1839-45.
47. Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB. Nature 1995; 376:167-70.
48. Tanaka M, Fuentes ME, Yamaguchi K, Durnin MH, Dalrymple SA, Hardy KL, Goeddel DV. Embryonic lethality, liver degeneration, and impaired NF-κB activation in IKK-β deficient mice. Immunity 1999; 10:421-429.
49. Doi TS, Marino MW, Takahashi T, Yoshida T, Sakakura T, Old LJ, Obata Y. Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality. Proc Natl Acad Sci 1999; 96:2994-99.
50. Rosenfeld ME, Prichard L, Shiojiri N, Fausto N. Prevention of hepatic apoptosis and embryonic lethality in RelA/TNFR-1 double knockout mice. Am J Pathol 2000; 156:997-1007.
51. Horowitz BH, Scott ML, Cherry SR, Bronson RT, Baltimore D. Failure of lymphopoiesis after adoptive transfer of NF-κB-deficient fetal liver cells. Immunity 1997; 6:765-72.
52. Grossmann M, Metcalf D, Merryfull J, Beg A, Baltimore D, Gerondakis S. The combined absence of the transcription factors Rel and RelA leads to multiple hemopoietic cell defects. Proc Natl Acad Sci 1999; 96:11848-53.
53. Senftleben U, Li ZW, Baud V, Karin M. Ikkβ is essential for protecting T cells from TNFα-induced apoptosis. Immunity 2001; 14:217-30.
54. Li Q, Verma IM. NF-κB regulation in the immune system. Nat Rev Immunol 2002; 2:725-34.
55. Sommer K, Guo B, Pomerantz JL, Bandaranayake AD, Moreno-Garcia ME, Ovechkina YL, Rawlings DJ. Phosphorylation of the CARMA1 linker controls NF-kappaB activation. Immunity 2005; 23:561-74.
56. Matsumoto R, Wang D, Blonska M, Li H, Kobayashi M, Pappu B, Chen Y, Wang D, Lin X. Phosphorylation of CARMA1 plays a critical role in T Cell receptor-mediated NF-kappaB activation. Immunity 2005; 23:575-85.
57. Croft M. Costimulatory members of the TNFR family: Keys to effective T-cell immunity? Nat Rev Immunol 2003; 3:609-20.
58. Hsu LC, Park JM, Zhang K, Luo JL, Maeda S, Kaufman RJ, Eckmann L, Guiney DG, Karin M. The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4. Nature 2004; 428:341-5.
59. Park JM, Greten FR, Wong A, Westrick RJ, Arthur JS, Otsu K, Hoffmann A, Montminy M, Karin M. Signaling pathways and genes that inhibit pathogen-induced macrophage apoptosis-CREB and NF-kappaB as key regulators. Immunity 2005; 23:319-29.
60. Zhang Y, Ting AT, Marcu KB, Bliska JB. Inhibition of MAPK and NF-kappa B pathways is necessary for rapid apoptosis in macrophages infected with Yersinia. J Immunol 2005; 174:7939-49.
61. Pasparakis M, Schmidt-Supprian M, Rajewsky K. IkappaB kinase signaling is essential for maintenance of mature B cells. J Exp Med 2002; 196:743-52.
62. Ren H, Schmalstieg A, Yuan D, Gaynor RB. I-kappa B kinase beta is critical for B cell proliferation and antibody response. J Immunol 2002; 168:577-87.
63. Li ZW, Omori SA, Labuda T, Karin M, Rickert RC. IKK beta is required for peripheral B cell survival and proliferation. J Immunol 2003; 170:4630-7.
64. Boothby MR, Mora AL, Scherer DC, Brockman JA, Ballard DW. Perturbation of the T lymphocyte lineage in transgenic mice expressing a constitutive repressor of nuclear factor (NF)-kappaB. J Exp Med 1997; 185(11):1897-907.
65. Ren H, Schmalstieg A, van Oers NS, Gaynor RB. I-kappa B kinases alpha and beta have distinct roles in regulating murine T cell function. J Immunol 2002; 168:3721-31.
66. Schmidt-Supprian M, Tian J, Grant EP, Pasparakis M, Maehr R, Ovaa H, Ploegh HL, Coyle AJ, Rajewsky K. Differential dependence of CD4+CD25+ regulatory and natural killer-like T cells on signals leading to NF-kappaB activation. Proc Natl Acad Sci USA 2004; 101:4566-71.
67. Stanic AK, Bezbradica JS, Park JJ, Matsuki N, Mora AL, Van Kaer L, Boothby MR, Joyce S. NF-kappa B controls cell fate specification, survival, and molecular differentiation of immunoregulatory natural T lymphocytes. J Immunol 2004; 172:2265-73.
68. Schmidt-Supprian M, Tian J, Ji H, Terhorst C, Bhan AK, Grant EP, Pasparakis M, Casola S, Coyle AJ, Rajewsky K. I kappa B kinase 2 deficiency in T cells leads to defects in priming, B cell help, germinal center reactions, and homeostatic expansion. J Immunol 2004; 173:1612-9.
69. Mason NJ, Artis D, Hunter CA. New lessons from old pathogens: What parasitic infections have taught us about the role of nuclear factor-kappaB in the regulation of immunity. Immunol Rev 2004; 201:48-56.
70. Lavon I, Goldberg I, Amit S, Landsman L, Jung S, Tsuberi BZ, Barshack I, Kopolovic J, Galun E, Bujard H, Ben-Neriah Y. High susceptibility to bacterial infection, but no liver dysfunction, in mice compromised for hepatocyte NF-kappaB activation. Nat Med 2000; 6:573-7.
71. Erdman S, Fox JG, Dangler CA, Feldman D, Horwitz BH. Typhlocolitis in NF-kappa B-deficient mice. J Immunol 2001; 166:1443-7.
72. Maeda S, Chang L, Li ZW, Luo JL, Leffert H, Karin M. IKKβ is required for prevention of apoptosis mediated by cell-bound but not circulating TNFα. Immunity 2003; 19:725-37.
73. Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 2005; 120:649-61.
74. Bubici C, Papa S, Pham CG, Zazzeroni F, Franzoso G. NF-kappaB and JNK: An intricate affair. Cell Cycle 2004; 3:1524-9.
75. Nakano H. Signaling crosstalk between NF-kappaB and JNK. Trends Immunol 2004; 25:402-5.
76. Chang L, Kamata H, Solinas G, Luo JL, Maeda S, Venuprasad K, Liu YC, Karin M. The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell 2006; 124:601-13.
77. Zerbini LF, Libermann TA. Life and death in cancer. GADD45 α and γ are critical regulators of NF-κB mediated escape from programmed cell death. Cell Cycle 2005; 4:18-20.
78. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005; 121:977-90.
79. Chen LW, Egan L, Li ZW, Greten FR, Kagnoff MF, Karin M. The two faces of IKK and NF-kappaB inhibition: Prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med 2003; 9:575-81.
80. Pasparakis M, Courtois G, Hafner M, Schmidt-Supprian M, Nenci A, Toksoy A, Krampert M, Goebeler M, Gillitzer R, Israel A, Krieg T, Rajewsky K, Haase I. TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature 2002; 417:861-6.
81. Dajee M, Lazarov M, Zhang JY, Cai T, Green CL, Russell AJ, Marinkovich MP, Tao S, Lin Q, Kubo Y, Khavari PA. NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 2003; 421:639-43.
82. Puel A, Picard C, Ku CL, Smahi A, Casanova JL. Inherited disorders of NF-kappaB mediated immunity in man. Curr Opin Immunol 2004; 16:34-41.
83. Ku CL, Yang K, Bustamante J, Puel A, von Bermuth H, Santos OF, Lawrence T, Chang HH, Al-Mousa H, Picard C, Casanova JL. Inherited disorders of human Toll-like receptor signaling: Immunological implications. Imm Rev 2005; 203:10-20.
84. Orange JS, Levy O, Geha RS. Human disease resulting from gene mutations that interfere with appropriate nuclear factor-kB activation. Imm Rev 2005; 203:21-37.
85. Stoffel A, Levine AJ. Activation by NF-κB by the Api2/MALT1 fusions inhibits p53 dependant but not FAS induced apoptosis. Cell Cycle 2004; 3:1017-1020.
86. Rocha S, Perkins ND. ARF the integrator. Linking NF-κB, p53 and checkpoint kinases. Cell Cycle 2005; 4:756-759.